[A case report of chronic myelomonocytic leukemia--therapeutic effect of VP 16-213 and cytosine arabinoside]. 1984

S Meguro, and T Chinen, and K Yokoyama, and N Takasaki, and N Mashizu, and H Ozeki, and D Nagamine, and K Aiba, and T Kobayashi, and Y Kuraishi

UI MeSH Term Description Entries
D007951 Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites. Granulocytic Leukemia,Leukemia, Granulocytic,Leukemia, Myelocytic,Leukemia, Myelogenous,Myelocytic Leukemia,Myelogenous Leukemia,Myeloid Leukemia,Leukemia, Monocytic, Chronic,Monocytic Leukemia, Chronic,Chronic Monocytic Leukemia,Chronic Monocytic Leukemias,Granulocytic Leukemias,Leukemia, Chronic Monocytic,Leukemias, Chronic Monocytic,Leukemias, Granulocytic,Leukemias, Myelocytic,Leukemias, Myelogenous,Leukemias, Myeloid,Monocytic Leukemias, Chronic,Myelocytic Leukemias,Myelogenous Leukemias,Myeloid Leukemias
D008297 Male Males
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy

Related Publications

S Meguro, and T Chinen, and K Yokoyama, and N Takasaki, and N Mashizu, and H Ozeki, and D Nagamine, and K Aiba, and T Kobayashi, and Y Kuraishi
September 1984, Cancer,
S Meguro, and T Chinen, and K Yokoyama, and N Takasaki, and N Mashizu, and H Ozeki, and D Nagamine, and K Aiba, and T Kobayashi, and Y Kuraishi
December 1984, European journal of cancer & clinical oncology,
S Meguro, and T Chinen, and K Yokoyama, and N Takasaki, and N Mashizu, and H Ozeki, and D Nagamine, and K Aiba, and T Kobayashi, and Y Kuraishi
May 1979, Blut,
S Meguro, and T Chinen, and K Yokoyama, and N Takasaki, and N Mashizu, and H Ozeki, and D Nagamine, and K Aiba, and T Kobayashi, and Y Kuraishi
August 1982, European journal of cancer & clinical oncology,
S Meguro, and T Chinen, and K Yokoyama, and N Takasaki, and N Mashizu, and H Ozeki, and D Nagamine, and K Aiba, and T Kobayashi, and Y Kuraishi
July 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
S Meguro, and T Chinen, and K Yokoyama, and N Takasaki, and N Mashizu, and H Ozeki, and D Nagamine, and K Aiba, and T Kobayashi, and Y Kuraishi
April 1986, Gan to kagaku ryoho. Cancer & chemotherapy,
S Meguro, and T Chinen, and K Yokoyama, and N Takasaki, and N Mashizu, and H Ozeki, and D Nagamine, and K Aiba, and T Kobayashi, and Y Kuraishi
May 1985, Gan no rinsho. Japan journal of cancer clinics,
S Meguro, and T Chinen, and K Yokoyama, and N Takasaki, and N Mashizu, and H Ozeki, and D Nagamine, and K Aiba, and T Kobayashi, and Y Kuraishi
June 1979, Cancer treatment reviews,
S Meguro, and T Chinen, and K Yokoyama, and N Takasaki, and N Mashizu, and H Ozeki, and D Nagamine, and K Aiba, and T Kobayashi, and Y Kuraishi
January 1990, Haematology and blood transfusion,
S Meguro, and T Chinen, and K Yokoyama, and N Takasaki, and N Mashizu, and H Ozeki, and D Nagamine, and K Aiba, and T Kobayashi, and Y Kuraishi
May 1984, The Medical letter on drugs and therapeutics,
Copied contents to your clipboard!